medigraphic.com
ISSN 1729-519X (Print)

2016, Number 6

<< Back Next >>

Revista Habanera de Ciencias Médicas 2016; 15 (6)

Hepatitis B and C virus’ infection in hemodialysed patients

La Rosa HD, Pérez PR, de la Cruz QB, Suárez CE, Hernández RO, Sayú CP, Turcaz BN, Dueñas RR, Vega SH, Sánchez CN, Arús FAE

Language: Spanish
References: 40
Page: 878-889
PDF size: 247.64 Kb.


ABSTRACT

Introduction: Patients subjected to hemodialysis treatment are a high risk group for hepatitis B and C infection.
Objective: To identify molecular and serologic markers of hepatitis B and C viral infection in hemodialysis patients.
Materials and Methods: Was performed an observational, descriptive, cross-sectional study including 103 patients with chronic kidney disease undergoing hemodialysis regime from Cuba’s Western and Central regions. The samples were received between January and April 2016 to study serologic and molecular markers of hepatitis B and C to be performed at the Gastroenterology’s Institute. Seroprevalence of anti HCV, HBsAg and Anti S was estimated, plus viral load determinations using amplification test to measuring nucleic acids DNA and RNA for hepatitis B and C respectively. Associations were evaluated using the χ2 statistician.
Results: 7.8% of hemodialysis patients were inactive carriers of hepatitis B. The 70.8% of patients had infection markers of hepatitis C virus; being hepatitis C hidden viremia in 18.4% of them.
Conclusions: High prevalence of infection and hepatitis C hidden viremia in hemodialysis patients.


REFERENCES

  1. Chien CC, Wang JJ, Sun YM, Sun DP, Sheu MJ, Weng SF, et al. Long-term survival and predictors for mortality among dialysis patients in an endemic area for chronic liver disease: a national cohort study in Taiwan. BMC nephrology. 2012;13:43.

  2. Duong CM, Olszyna DP, McLaws ML. Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC public health. 2015;15:192.

  3. Ekrikpo UE, Udo AI, Ikpeme EE, Effa EE. Haemodialysis in an emerging centre in a developing country: a two year review and predictors of mortality. BMC nephrology. 2011;12:50.

  4. Rolando J OQ. Hepatitis C en hemodiálisis. Rev Col Gatroeneterol. 2005;20(1):34-50.

  5. Barrios Camba J, Leyva de la Torre C, Chávez Moreno NJ, Cabrera Yero Y, Márquez Márquez DR. Infección por virus de la hepatitis b y c en pacientes de hemodiálisis. Revista de Ciencias Médicas de Pinar del Río. 2008;12:48-60.

  6. Begué Dalmau NMFC, N G. Méndez Leyva, L.Martí Rodríguez, L A. Pinto Martínez,D M. Caracterización de pacientes con hepatitis B y C en hemodiálisis MEDISAN. 2016;20(2):161.

  7. Alashek WA, McIntyre CW, Taal MW. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC infectious diseases. 2012;12:265.

  8. Calisti G, Herman O, Powley M, Haque T. Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster. BMJ case reports. 2014;2014.

  9. Cao YL, Wang SX, Zhu ZM. Hepatitis B viral infection in maintenance hemodialysis patients: a three year follow-up. World journal of gastroenterology. 2007;13(45):6037-40.

  10. Da Silva NM, Germano FN, Mendoza-Sassi RA, Seuanez HN, Soares MA, de Martinez AM. Evidence of association between hepatitis C virus genotype 2b and nosocomial transmissions in hemodialysis centers from southern Brazil. Virology journal. 2013;10:167.

  11. Elghannam DM, Aly RM, Goda EF, Eltoraby EE, Farag RE. Clinical significance of antibody to hepatitis B core antigen in multitransfused hemodialysis patients. Asian journal of transfusion science. 2009;3(1):14-7.

  12. Mostaghni AA, Soltanian A, Mokhtari E, Japoni S, Mehrabani D. Seroprevalence of hepatitis B virus among hemodialysis patients in Bushehr province, southern Iran: HBV seroprevalence in hemodialysis patients. Hepatitis monthly. 2011;11(3):200-2.

  13. Navarro JF, Teruel JL, Mateos M, Ortuno J. Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients. Clinical nephrology. 1994;41(2):113-6.

  14. Romero S G. Hepatitis C y B en pacientes con insuficiencia renal crónica y trasplante renal: Historia natural y decisiones terapéuticas. Gen. 2012;66:63-9.

  15. Sulbarán MZ, Farías YdV, Sulbarán Y, Flores CR, Zerpa J, Maldonado A, et al. Infección por el virus de la hepatitis C (HCV) en pacientes hemodializados seronegativos para anticuerpos anti-HCV. Revista de la Sociedad Venezolana de Microbiología. 2015;35:51-5.

  16. Salvatierraa KF, H. Análisis del virus de la hepatitis C en pacientes en hemodiálisis. Infectio. 2016;20(3):130-7.

  17. Estenoz Odio M, Garlobo Rosales DM. Factores de riesgo epidemiológico de hepatitis C en pacientes hemodializados MEDISAN. 2010;14(4):464.

  18. Carvalho-Filho RJ, Feldner AC, Silva AE, Ferraz ML. Management of hepatitis C in patients with chronic kidney disease. World journal of gastroenterology. 2015;21(2):408-22.

  19. Loza Munárriz C, Depaz Dolores M, Suárez Jara M, Loza Munárriz R, Valenzuela Córdova R, Bravo Tejada J, et al. Frecuencia de marcadores serológicos de hepatitis viral B y C en pacientes que ingresan por primera vez al programa de hemodiálisis en el Hospital Nacional Cayetano Heredia. Revista de Gastroenterología del Perú. 2005;25:320-7.

  20. Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. World journal of hepatology. 2015;7(3):548-58.

  21. World Medical Association Declaration of Helsinki.Ethical principles for medical research involving human subjects. WMA. 2013.

  22. Sette LH, Almeida Lopes EP. Liver enzymes serum levels in patients with chronic kidney disease on hemodialysis: a comprehensive review. Clinics (Sao Paulo). 2014;69(4):271-8.

  23. Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients. World journal of gastroenterology. 2014;20(34):12018-25.

  24. Mina P, Georgiadou SP, Rizos C, Dalekos GN, Rigopoulou EI. Prevalence of occult hepatitis B virus infection in haemodialysis patients from central Greece. World journal of gastroenterology. 2010;16(2):225-31.

  25. Pereira ZT, Mendoza-Sassi RA. [Factors associated with the immune response to hepatitis B vaccine in Brazilian hemodialysis patients]. Revista medica de Chile. 2012;140(7):882-8.

  26. Gasim GI, Bella A, Adam I. Immune response to hepatitis B vaccine among patients on hemodialysis. World journal of hepatology. 2015;7(2):270-5.

  27. Grzegorzewska AE, Wobszal PM, Sowinska A, Mostowska A, Jagodzinski PP. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Molecular biology reports. 2013;40(12):6899-911.

  28. Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC nephrology. 2012;13:97.

  29. Sit D, Esen B, Atay AE, Kayabasi H. Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy. World journal of hepatology. 2015;7(5):761-8.

  30. Somi MH, Hajipour B. Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants. ISRN gastroenterology. 2012.

  31. Bose B, McDonald SP, Hawley CM, Brown FG, Badve SV, Wiggins KJ, et al. Effect of dialysis modality on survival of hepatitis C-infected ESRF patients. Clinical journal of the American Society of Nephrology : CJASN. 2011;6(11):2657-61.

  32. Milián Figueroa IN, Betancourt García M, Dávila Véliz Y. Hepatitis C en pacientes hemodializados: una mirada actual. Revista Médica Electrónica. 2011;33:484-98.

  33. Cieza J PF, Hinostroza J,Estremadoyro L, Loza C. Factores de riesgo para infección por hepatitis C en dos Unidades de diálisis de Lima-Perú. RevMedExp. 2001;18(1-2):5-9.

  34. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut. 1996;38 Suppl 2:S48-55

  35. J. Fernández PG, N. del Pino, N. Cavalli, C. Alberro, P. Rendo, L. Viola. Infección por el virus de la hepatitis C en pacientes de hemodiál isis: hallazgos epidemiológicos, clínicos e histológicos. Nefrología : publicación oficial de la Sociedad Española Nefrología. 1996;XVl(4).

  36. Capote Pereira LL, Morejón Palacio E, Mora González S, Castañer Moreno J, Teuma Cortes I, Rodríguez Batista R. Factores de riesgo para la transmisión de la hepatitis C en hemodiálisis. Revista Cubana de Medicina. 2005;44.

  37. Pérez Escobar MM, Herrera Cruz N, Pérez Escobar E, Cabrejas Hernández Z. Factores sociales que contribuyen a la morbi-mortalidad en pacientes con Insuficiencia Renal Crónica sometidos a hemodiálisis. Un estudio necesario. Humanidades Médicas. 2008;8.

  38. Vidales-Braz BM,Da Silva NM, Lobato R, Germano FN, da Mota LD, Barros EJ, et al. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virology journal. 2015;12:8.

  39. Kwon E, Cho JH, Jang HM, Kim YS, Kang SW, Yang CW, et al. Differential Effect of Viral Hepatitis Infection on Mortality among Korean Maintenance Dialysis Patients: A Prospective Multicenter Cohort Study. PloS one. 2015;10(8):e0135476.

  40. Berenguera M, Serrac MA, Solad R y Castellano G. Tratamiento de la hepatitis C en grupos de pacientes especiales. Gastroenterol Hepatol. 2014;37(1):23-36.




2020     |     www.medigraphic.com